Plain-English translation of NCT06466135 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This clinical trial is testing a new medication called to see if it can help treat several types of glomerular kidney disease—conditions where the filtering units in your kidneys become damaged and allow too much protein to leak into your urine. Researchers want to learn whether this medication is safe and effective, and how your body processes it. About 96 people with these kidney conditions will participate.
Many people with glomerular kidney diseases don't have enough treatment options, and their kidney function continues to decline over time. This medication is being studied because early research suggests it might help protect the kidneys and reduce protein loss, potentially slowing disease progression.
You likely qualify if…
You likely don't qualify if…
You will receive either the new medication or a placebo as an intravenous infusion (through an IV) once every 2 weeks for a total of 7 infusions over about 3 months. After your last infusion, you'll continue to be monitored for 24 weeks (about 6 months) to see how the treatment affects your kidneys and overall health. The study team will track whether the medication reduces protein in your urine and watch for any side effects.
AI-generated summary from trial data · Aug 22, 2026 · Not medical advice
United States